PFE241206P35000
- 0.00
- 0.000.00%
Pfizer Newsroom
Leerink Partners Maintains Pfizer(PFE.US) With Hold Rating, Announces Target Price $28
Cautious Outlook: Pfizer's EPS Downgrade and Conservative Guidance Prompt Hold Rating
Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know
Pfizer Options Spot-On: On December 11th, 215.48K Contracts Were Traded, With 3.54 Million Open Interest
Nasdaq Surges Past 20,000 for the First Time, Powered by Tech Giants | Wall Street Today
Pfizer's Options: A Look at What the Big Money Is Thinking
Amazon, Pfizer Execs Seek Common Ground With RFK Jr on Climate Risks to Health
10 Health Care Stocks Whale Activity In Today's Session
Pfizer Is Maintained at Buy by Guggenheim
Pfizer Analyst Ratings
Express News | Reuters Next - Pfizer's Roan Says Unh Exec's Murder Was a "Tragedy of Epic Proportions"
Express News | Reuters Next - Pfizer's Roan Says We Need to Get Behind the Disease Prevention Message
Express News | Reuters Next - Pfizer's Roan Says Going to Work Hard to Ensure Ecosystem That Drives Vaccines & New Medicines Is Robust and Healthy
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Express News | Reuters Next - Pfizer Chief Sustainability Officer Caroline Roan Says Need to Double Down on Climate Investments in Low Income Countries
Guggenheim Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $33
Pfizer Price Target Lowered to $33 From $35 at Guggenheim
Evercore Maintains Pfizer(PFE.US) With Buy Rating
Pfizer (PFE) Gets a Buy From Evercore ISI
NCCN Announces Funding for a Prostate Cancer Research Project